Analyzing Ritter Pharmaceuticals (RTTR) & The Competition

Ritter Pharmaceuticals (NASDAQ: RTTR) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Ritter Pharmaceuticals to similar companies based on the strength of its earnings, profitability, valuation, institutional ownership, dividends, analyst recommendations and risk.

Valuation & Earnings

This table compares Ritter Pharmaceuticals and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Ritter Pharmaceuticals N/A -$18.38 million -0.30
Ritter Pharmaceuticals Competitors $290.27 million $35.99 million 55.49

Ritter Pharmaceuticals’ peers have higher revenue and earnings than Ritter Pharmaceuticals. Ritter Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

33.4% of Ritter Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 28.1% of Ritter Pharmaceuticals shares are held by insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Ritter Pharmaceuticals and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ritter Pharmaceuticals 0 1 4 0 2.80
Ritter Pharmaceuticals Competitors 1134 3426 11925 240 2.67

Ritter Pharmaceuticals currently has a consensus target price of $2.50, suggesting a potential upside of 608.22%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.63%. Given Ritter Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Ritter Pharmaceuticals is more favorable than its peers.

Risk and Volatility

Ritter Pharmaceuticals has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Ritter Pharmaceuticals’ peers have a beta of 2.37, indicating that their average share price is 137% more volatile than the S&P 500.


This table compares Ritter Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ritter Pharmaceuticals N/A -480.51% -235.87%
Ritter Pharmaceuticals Competitors -5,443.85% -164.39% -36.43%


Ritter Pharmaceuticals peers beat Ritter Pharmaceuticals on 8 of the 13 factors compared.

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health. The Company’s compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply